retatrutide trial news 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide Results: 28.3% Weight Loss

Our Products Variety of Flavors: Enjoy a wide selection of sweet, savory, and crunchy options to keep your meals interesting

GLP-1 therapy should only be used under the guidance of a licensed healthcare provider who can evaluate your medical history and determine whether this treatment is appropriate for you

We work with a wide range of patients from all backgrounds and are known for our commitment to diversity

While details are still being finalized, this marks an important step forward in expanding access to obesity care

In some cases, these sensory symptoms are early signs of an attack

[DOI] [PubMed] [Google Scholar] 33